Orthocell (OCC) Q4 2026 TU earnings summary

Executive summary

• Achieved record quarterly revenue of $3.8 million for June 2026, up 20% sequentially and 36% year-over-year; FY2026 revenue reached $13.2 million, a 44% increase from FY2025, driven by Remplir and Striate+ sales in Australia, the US, and new international markets.

• U.S. commercialisation of Remplir is ahead of expectations, with distributor coverage now reaching 50% of the U.S. population and hospital adoption accelerating.

• Expanded global reach with new distributor appointments in Canada and Thailand, and regulatory progress in the UK/EU and Latin America.

• Strong liquidity position with $44.1 million in funds available as of 30 June 2026, supporting ongoing commercial expansion and R&D activities.

Financial highlights

• June quarter revenue of $3.8 million, up 20% from March quarter and 36% from Q4 FY2025.

• FY2026 revenue of $13.2 million, a 44% increase year-over-year.

• Cash receipts from customers totaled $2.5 million for the quarter, up from $1.6 million in the prior quarter.

• Net operating cash outflow of $3.7 million for the quarter, with normalised cash burn stable at $2.4 million after adjusting for non-recurring items.

• Funds available at quarter-end were $44.1 million, including $9.4 million in cash and $34.7 million in term deposits.

Outlook and guidance

• Anticipates continued revenue growth in FY2027, driven by further U.S. hospital adoption and surgeon utilisation.

• Regulatory approval for Remplir in the UK/EU expected by end of CY2026, unlocking a major market.

• Commercial launches of Striate+ in Brazil, Colombia, and Ecuador expected in 2H CY2026.

• U.S. regulatory program for a tendon repair application underway, expanding the addressable market.